Therapeutic drug monitoring of regorafenib and its metabolite M5 can predict treatment efficacy and the occurrence of skin toxicities.
Daiki TaguchiMasahiro InoueKoji FukudaTaichi YoshidaKazuhiro ShimazuKazuma FujitaHiroyuki OkuyamaNobuhisa MatsuhashiAkihito TsujiKazuhiro YoshidaMasatomo MiuraHiroyuki ShibataPublished in: International journal of clinical oncology (2019)
The use of regorafenib may not be suitable in patients with a low Ctrough value. To prevent skin toxicities, the Ctrough value of M5 should be monitored.